COPENHAGEN (Reuters) - Novo Nordisk (NYSE:) expects to close its acquisition of Catalent (NYSE:) later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.